SELLAS Life Sciences (SLS) stock falls following interim results from a Phase 3 REGAL trial for its lead asset, galinpepimut-S (GPS)
https://seekingalpha.com/news/4397943-sellas-life-sciences-stock-falls-gps-data
SELLAS Life Sciences (SLS) stock falls following interim results from a Phase 3 REGAL trial for its lead asset, galinpepimut-S (GPS)
https://seekingalpha.com/news/4397943-sellas-life-sciences-stock-falls-gps-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.